Endgame polio - Vaccine strategies to achieve an end  by Modlin, J.
62 16th ICID Abstracts / International Journal of Infectious Diseases 21S (2014) 1–460
by combining several of these proteins were found to be associ-
ated with fewer reactions and were efﬁcacious. Acellular vaccines
soon replaced whole cell vaccines in many countries, but because
of reduced cost and proven efﬁcacy, whole cell vaccines are still
used inmost developing countries. Therehas been a recent increase
in reported pertussis cases observed in many countries using the
acellular vaccines, especially in young adolescents between 7 to 14
years of age. The reasons for this increase are complex and mul-
tifactorial and include greater intensity of surveillance, improved
method to diagnose pertussis, changes in the biologic charac-
teristics of the Bordetella pertussis organisms, and the types and
schedules of pertussis vaccines used for routine vaccination. Cur-
rent acellular vaccines have been shown to be efﬁcacious in the
short term, but in actual use are failing to be effective in controlling
pertussis in the long term. Recent data suggest that the acellu-
lar vaccines are associated with more rapid waning of immunity,
and that priming with whole cell pertussis vaccine is more effec-
tive than acellular vaccine in preventing disease. There is a clear
need to better understand the differences in the immune responses
induced by acellular and whole cell vaccines after both the pri-
mary and booster series. Nonhuman primate models are shedding
light on the differences in the prevention of disease and transmis-
sion with acellular and whole cell vaccines and on the differences
in immune responses to both vaccine types. Strategies to improve
the current acellular vaccines include; reintroduction of whole cell
vaccines into the vaccine series, the addition of new antigens to
the currently available acellular vaccines, the use of adjuvants to
enhance speciﬁc immune responses, and the utility of a new live
attenuated intranasal pertussis vaccine
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Dengue vaccine development: An update
A. Wilder-Smith
Lee Kong Chian School of Medicine, Singapore,
Singapore
Recent estimates on the burden of DENV infection deter-
mined that there are 390 million dengue infections per year,
three times the current estimate by the WHO. Since vector
control programs have been largely unsuccessful in preventing
outbreaks, vaccination seems to be the most viable option for
prevention. The development of dengue vaccines has been ham-
pered by the theoretical risk of vaccine-related adverse events
such as immune enhancement, and the requirement to induce a
long-lasting protective immune response against all four dengue
serotypes simultaneously. Other challenges include the lack of an
adequate animal model of disease, absence of an immune corre-
late of protection, and only partially informative immunogenicity
assays. Currently, several kinds of dengue vaccines are in develop-
ment, but only one of these candidates (a chimeric dengue-yellow
fever live attenuated vaccine) has reached the stage of phase 3 clin-
ical trials. Live dengue vaccine candidates have been administered
to ten thousands of volunteers and were well-tolerated, with mini-
mal short-termsafetyeffects reported inPhase I andPhase II clinical
trials. Based on the natural history of dengue, a theoretical possi-
bility of an increased risk of severe dengue as a consequence of
vaccination has been hypothesized but not yet observed. Despite
good safety and immunogenicity proﬁles registered, issues such as
imbalanced immune responses between serotypes and lack of clin-
ical protective efﬁcacy in the ﬁrst results of Phase 3 trials have been
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As of December 18, 360 cases of wild type 1 poliomyelitis
and 58 cases of paralysis caused by circulating vaccine-derived
polioviruses (cVDPV) were reported to WHO in 2013 compared
with 223 wild type and 70 cVDPV in calendar year 2012. No wild
type 3 cased occurred and all cVDPV cases were attributed to type
2 Sabin derived strains. Among the 3 endemic countries, Nigeria
and Afghanistan made substantive progress in controlling WPV1
disease with year-over-year reductions of 58% and 68%, respec-
tively, and further localization of areas experiencing endemic cases.
In contrast, Pakistan recorded 75 new cases, an increase of 34%
over 2012 due to outbreaks in areas affected by insecurity and
poor access to unvaccinated children. New WPV1 outbreaks in the
Horn of Africa (203 cases) and Syria (17 cases) were attributed to
export of WPV1 viruses from Nigeria and Pakistan, respectively,
and 4 cases of paralysis occurred in Cameroon, caused by a WPV1
strain that had been circulating undetected for an estimated 2-3
years.WPV1viruses related to the Syrianoutbreakweredetected in
environmental surveillance samples beginning in May, 2013 with-
out evidence of paralytic disease in this highly vaccinated country.
In response, the Israeli Ministry of Health has re-introduced OPV
into the national immunization schedule.
Insecurity, threats to polio vaccination teams, and gaps in sup-
plemental immunization activity (SIA) campaign quality are now
major obstacles to eradication which are being addressed by the
GPEI in multiple ways including engagement of government and
religious leaders and other relevant third parties, and introduction
of methods to assess and improve SIA coverage. Ongoing recovery
of cVDPV viruses from children with acute ﬂaccid paralysis (AFP)
and from environmental surveillance specimens in under immu-
nized areas will mean that cessation of all OPV immunization will
need to cease in a globally coordinated manner. The 2013-2018
GPEI Strategic Plan calls for complete control of all wild poliovirus
transmission the end of 2014, introduction of one or more IPV
doses for routine immunization by Q3 2015 for risk mitigation, and
replacement of all trivalent OPV with bivalent type 1 and 3 OPV
in Q2 2016. With global certiﬁcation of eradication by the end of
2018, all OPV vaccines will be discontinued and replaced by IPV.
New tools to assist in achieving and maintaining eradication
areunderdevelopment includingnew, affordable IPV formulations,
genetically stable OPV vaccines derived from current Sabin strains,
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and anti-poliovirus drugs to reduce the risk of reintroduction VDPV
viruses from chronically infected immunodeﬁcient persons.
http://dx.doi.org/10.1016/j.ijid.2014.03.550
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The global burden of inﬂuenza is substantial. Ample data from
high resource settings supports that inﬂuenza infection leads
to hospitalizations, deaths, excess medication usage, and days
missed from work and school on an annual basis. Likewise, there
is an increasing recognition of the high inﬂuenza burden in low
resource countries, although most of our knowledge is limited to
the direct effects of inﬂuenza illness and less is known about the
indirect effects on school or work productivity or the ﬁnancial
consequences.
Inﬂuenza is a preventable disease, and advisory bodies
throughout the world, including the World Health Organization,
recommend inﬂuenza vaccine for various age groups and risk
groups within the population. In 2013, an unprecedented num-
ber of inﬂuenza vaccines are available on the worldwide market,
including quadrivalent vaccines, live-attenuated vaccines, high
dose vaccines, vaccines administered intradermally and vaccines
manufactured in cell culture. Many more inﬂuenza vaccines are in
development, and it is anticipated that the diversity of inﬂuenza
vaccine choices will continue to increase. Comparative trials are
beginning to elucidate the relative beneﬁts of certain vaccines in
particular age groups and populations.
This talk will focus on the deployment of particular vaccines
and novel strategies to improve inﬂuenza prevention programs.
The relative advantages anddisadvantagesofdifferent vaccines and
vaccination strategies will be discussed, with a look into the future
of inﬂuenza vaccine control in various settings.
http://dx.doi.org/10.1016/j.ijid.2014.03.551
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New trends in the treatment of infectious
diseases caused by antibiotic resistant bacteria
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Multidrug resistant (MDR) bacteria are a major concern in the
worldwide. There remain some useful antibiotics for infectious dis-
eases caused by MDR Gram-positive organisms. On the other hand,
treatment of infections caused by MDR Gram-negative bacteria
is quite a predicament because the number of effective antibi-
otics is limited. One of the options is colistin. A lot of articles
have reported neurotoxicity or nephrotoxicity with colistin. The
injectable colistin does not show enough efﬁciency for treating
pneumonia, because this drug attains low concentrations in the
lung. Furthermore, some organisms, including Proteae and Serratia
spp., show natural resistance for colistin. Colistin is not com-
mercially available in Japan. Another option is tigecycline. This
compound shows antibiotic activity against both Gram-negative
organisms and Gram-positive organisms. Unfortunately, this drug
does not show antibiotic activity against Pseudomonas aeruginosa.
More therapeutic options are needed. We ﬁrst constructed a tool
for ﬁnding combination antibiotics by the modiﬁed checker board
method. In Japan, the combination of amikacin and aztreonam
is most effective combination for MDR P. aeruginosa including
metallo-beta-lactamase (MBL)producers.Anotheruseful option for
MBL producing organisms is the combination of Braian® (EDTA-
calcium) and beta-lactams, such as imipenem or ceftazidime. The
effectivenessof this combinationhasbeenconﬁrmedby invitroand
invivo experimentsusing themurine experimentalmodel. Another
problem for infectious diseases by Gram-negative organism is
endotoxin shock. Polymixycins can capture the lipopolysaccha-
rides of Gram-negative bacteria. We have evaluated continuously
infused lowdoes colistin usingmicrosphere in themurine infection
model.Ourdata suggests that colistin canprotect against endotoxin
shock. In thispresentation,wediscuss thesenovel treatment strate-
gies against infectious diseases caused by MDR Gram-negative
organisms.
http://dx.doi.org/10.1016/j.ijid.2014.03.553
